Elacytarabine Failure Leaves Clavis Scrambling For Buyer
This article was originally published in The Pink Sheet Daily
Executive Summary
The Phase III failure of Clavis’ AML candidate elacytarabine likely spells the end of the road for the Norwegian company and its lipid vector technology approach to drug development. Clavis is aiming to find a buyer or merger option or considering closing its doors.
You may also be interested in...
Clavis/Clovis' Pancreatic Cancer Drug Fails Despite Personalized Medicine Approach
The failure of Clavis Pharma's and Clovis Oncology's novel potential pancreatic cancer therapy CP-4126/CO-101 in the pivotal LEAP trial was associated with the surprising failure of a novel personalized medicine approach to treating the devastating disease.
Pink Sheet Podcast: COVID-19 Stresses Manufacturing, Vaccine Placebo Controls, Thorny FDA Precedents
Pink Sheet reporters and editor discuss the pandemic’s effects on non-coronavirus-related product manufacturing, US FDA efforts to ensure vaccine sponsors maintain placebo controls once a product is available, and precedents that burden the agency.
Novavax Push For COVID-19 Vaccine Manufacturing Capacity Delays Flu Vaccine Application
As CEO Erck touts that its COVID vaccine has the 'best data,' Novavax prepares to enter Phase III trials and inks deal with Serum Institute to boost production even as its 'almost a perfect flu vaccine' remains on hold.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: